Our strategy is to harness the full breadth of Wnt potential by identifying disease states responsive to Wnt pathway modulation, design tissue-specific antibodies, and advance candidates into clinical development in indications with high unmet need.
The following table highlights our lead programs.
The following table highlights our identified research programs.
IBD: Inflammatory Bowel Disease; AMD: Age-related Macular Degeneration; RPE: Retinal Pigment Epithelium; IPF: Idiopathic Pulmonary Fibrosis; COPD: Chronic Obstructive Pulmonary Disease; FSGS: Focal Segmental Glomerulosclerosis; DME: Diabetic Macular Edema
Surrozen’s novel approach to modulating the Wnt pathway may lead to therapeutics that reverse the effects of serious diseases by repairing damaged tissue, restoring organ function and renewing a patient’s health, and hope, for an improved quality of life.
Repair. Restore. Renew.™